Ace the Case: A 24-Year-Old Man With a History of Ulcerative Colitis and Abnormal Liver Tests healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
E-Mail
ATS 2021, New York, NY - By removing race correction from the interpretation of pulmonary function test (PFT) results, Black individuals were shown to have a significantly higher prevalence and severity of lung disease, according to research presented at the ATS 2021 International Conference.
Alexander Moffett, MD, clinical fellow, Division of Pulmonary, Allergy and Critical Care, University of Pennsylvania Perelman School of Medicine, and colleagues, sought to determine the real-world consequences of race correction for the interpretation of PFT results. Race correction, a standard practice in PFT interpretation that has no biological basis, results in a decrease in the predicted lower limit of normal for FEV1 (the maximum amount of air a person can forcibly exhale in one second) and FVC (forced vital capacity maximum amount exhaled forcefully after breathing in deeply) for Black patients.
ABC News
Turn on desktop notifications for breaking stories about interest?
OffOn
Experts say a key strategy must accompany the perks.
• 9 min read
By the Numbers: Vaccine incentives
A look at some of the giveaways around the country being offered to encourage more COVID-19 vaccinations. SOPA Images/LightRocket via Getty Images, FILE
With vaccination numbers declining across the country, leaders in various states are scrambling to put a stick and carrot in front of the millions of residents who have yet to get the shots.
From free beers and baseball tickets to a raffle for a car and even cash, governors and city leaders are attempting to encourage those on the fence to roll up their sleeves. But so far, states have not seen upticks in their vaccine administrations, according to data from the Centers for Disease Control and Prevention.
BRCA variants, results of a small phase II trial showed.
A patient cohort with germline and somatic mutations, including
PALB2, had a 6-month progression-free survival (PFS) of 59.5%, decreasing only slightly to 54.5% at 12 months with maintenance rucaparib (Rubraca). The overall response rate of 41.7% included patients with germline (g) and somatic (s)
BRCA1/2 mutations and those with
PALB2 variants. Two-thirds of patients obtained disease control with the PARP inhibitor, according to Kim A. Reiss, MD, of University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues.
The results supported and extended those from the practicing-changing POLO trial of olaparib (Lynparza) maintenance for g